[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fP9hzIOcZyYHR-hUWZ0bp6GAy7MFlZegpHuEd2ZG09v4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"Janssen Korea, Ltd., Korea",[4],77,false,2,3,39719,6,[13,16,19,21,24,26,28,30],{"name":14,"count":15},"Schizophrenia",11,{"name":17,"count":18},"Pain",7,{"name":20,"count":11},"Multiple Myeloma",{"name":22,"count":23},"Healthy",4,{"name":25,"count":9},"Epilepsy",{"name":27,"count":9},"Chronic Pain",{"name":29,"count":9},"Neutropenia",{"name":31,"count":8},"Cancer Pain",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT07053345","A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression","2027-06-25","Esketamine 56 mg",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,71,89,140,184,208,231,255,279,306,324,342,367,391,409,435,453,471,495,513,538,556,581,606,631,655,681,699,722,745,770,788,814,832,857,891,915,938,956,1041,1101,1144,1185,1221,1258,1289,1320,1352,1377,1401,1423,1446,1471,1489,1512,1539,1557,1586,1611,1629,1647,1671,1689,1707],{"intervention":37,"totalTrials":47,"cells":48},1,{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":58,"NA":69},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[],{"trials":57,"activeCount":51},[],{"trials":59,"activeCount":47,"soonestReadout":36},[60],{"nctId":34,"briefTitle":35,"status":61,"phases":62,"primaryCompletion":36,"completion":36,"start":63,"enrollment":64,"conditions":65,"interventions":67},"RECRUITING",[43],"2025-06-09",47,[66],"Depressive Disorder, Treatment-Resistant",[37,68],"Esketamine 84 mg",{"trials":70,"activeCount":51},[],{"intervention":68,"totalTrials":47,"cells":72},{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":87},{"trials":74,"activeCount":51},[],{"trials":76,"activeCount":51},[],{"trials":78,"activeCount":51},[],{"trials":80,"activeCount":51},[],{"trials":82,"activeCount":47,"soonestReadout":36},[83],{"nctId":34,"briefTitle":35,"status":61,"phases":84,"primaryCompletion":36,"completion":36,"start":63,"enrollment":64,"conditions":85,"interventions":86},[43],[66],[37,68],{"trials":88,"activeCount":51},[],{"intervention":90,"totalTrials":23,"cells":91},"Paliperidone",{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":96,"PHASE3":98,"PHASE4":100,"NA":138},{"trials":93,"activeCount":51},[],{"trials":95,"activeCount":51},[],{"trials":97,"activeCount":51},[],{"trials":99,"activeCount":51},[],{"trials":101,"activeCount":51},[102,113,121,130],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":112},"NCT00761579","Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission","COMPLETED",[43],"2010-10","2010-12","2008-04",190,[14],[90],{"nctId":114,"briefTitle":115,"status":105,"phases":116,"primaryCompletion":117,"completion":107,"start":109,"enrollment":118,"conditions":119,"interventions":120},"NCT00761605","Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants",[43],"2010-09",387,[14],[90],{"nctId":122,"briefTitle":123,"status":105,"phases":124,"primaryCompletion":125,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":129},"NCT00761189","PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia",[43],"2010-07","2008-02",491,[14],[90],{"nctId":131,"briefTitle":132,"status":105,"phases":133,"primaryCompletion":108,"completion":134,"start":109,"enrollment":135,"conditions":136,"interventions":137},"NCT00784238","Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants",[43],"2011-01",289,[14],[90],{"trials":139,"activeCount":51},[],{"intervention":141,"totalTrials":9,"cells":142},"risperidone",{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":151,"NA":182},{"trials":144,"activeCount":51},[],{"trials":146,"activeCount":51},[],{"trials":148,"activeCount":51},[],{"trials":150,"activeCount":51},[],{"trials":152,"activeCount":51},[153,162,172],{"nctId":154,"briefTitle":155,"status":105,"phases":156,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":161},"NCT00216528","A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres",[43],"2007-04","2005-07",527,[14],[141],{"nctId":163,"briefTitle":164,"status":105,"phases":165,"primaryCompletion":108,"completion":108,"start":166,"enrollment":167,"conditions":168,"interventions":169},"NCT00992407","An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder",[43],"2007-12",75,[14],[170,171],"Risperidone long acting injectables","Risperidone",{"nctId":173,"briefTitle":174,"status":105,"phases":175,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":181},"NCT00216554","The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania",[43],"2006-03","2004-09",118,[180],"Bipolar Disorder",[141],{"trials":183,"activeCount":51},[],{"intervention":185,"totalTrials":47,"cells":186},"Paliperidone palmitate",{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":206},{"trials":188,"activeCount":51},[],{"trials":190,"activeCount":51},[],{"trials":192,"activeCount":51},[],{"trials":194,"activeCount":51},[],{"trials":196,"activeCount":51},[197],{"nctId":198,"briefTitle":199,"status":105,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":205},"NCT01682161","A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate",[43],"2013-09","2012-01",154,[14],[185],{"trials":207,"activeCount":51},[],{"intervention":209,"totalTrials":47,"cells":210},"Hydromorphone",{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":229},{"trials":212,"activeCount":51},[],{"trials":214,"activeCount":51},[],{"trials":216,"activeCount":51},[],{"trials":218,"activeCount":51},[],{"trials":220,"activeCount":51},[221],{"nctId":222,"briefTitle":223,"status":105,"phases":224,"primaryCompletion":225,"completion":225,"start":226,"enrollment":110,"conditions":227,"interventions":228},"NCT00766831","An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain",[43],"2010-06","2008-10",[31],[209],{"trials":230,"activeCount":51},[],{"intervention":232,"totalTrials":47,"cells":233},"Fentanyl D-trans",{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":242,"NA":253},{"trials":235,"activeCount":51},[],{"trials":237,"activeCount":51},[],{"trials":239,"activeCount":51},[],{"trials":241,"activeCount":51},[],{"trials":243,"activeCount":51},[244],{"nctId":245,"briefTitle":246,"status":105,"phases":247,"primaryCompletion":248,"completion":248,"start":157,"enrollment":249,"conditions":250,"interventions":252},"NCT01060124","An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics",[43],"2009-02",103,[251],"Pain; Cancer",[232],{"trials":254,"activeCount":51},[],{"intervention":256,"totalTrials":47,"cells":257},"Fentanyl-TTS",{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":264,"PHASE4":266,"NA":277},{"trials":259,"activeCount":51},[],{"trials":261,"activeCount":51},[],{"trials":263,"activeCount":51},[],{"trials":265,"activeCount":51},[],{"trials":267,"activeCount":51},[268],{"nctId":269,"briefTitle":270,"status":105,"phases":271,"primaryCompletion":272,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":276},"NCT01902524","Efficacy and Safety Study of Fentanyl Transdermal Patch for Treatment of Chronic Pain",[43],"2006-11","2005-10",65,[27],[256],{"trials":278,"activeCount":51},[],{"intervention":280,"totalTrials":47,"cells":281},"Topiramate Standard",{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":290,"NA":304},{"trials":283,"activeCount":51},[],{"trials":285,"activeCount":51},[],{"trials":287,"activeCount":51},[],{"trials":289,"activeCount":51},[],{"trials":291,"activeCount":51},[292],{"nctId":293,"briefTitle":294,"status":105,"phases":295,"primaryCompletion":296,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":301},"NCT01060111","An Efficacy and Tolerability Study of Topiramate in Participants With Migraine",[43],"2008-07","2006-07",250,[300],"Migraine",[280,302,303],"Topiramate Slow","Propranolol booster",{"trials":305,"activeCount":51},[],{"intervention":302,"totalTrials":47,"cells":307},{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":322},{"trials":309,"activeCount":51},[],{"trials":311,"activeCount":51},[],{"trials":313,"activeCount":51},[],{"trials":315,"activeCount":51},[],{"trials":317,"activeCount":51},[318],{"nctId":293,"briefTitle":294,"status":105,"phases":319,"primaryCompletion":296,"completion":296,"start":297,"enrollment":298,"conditions":320,"interventions":321},[43],[300],[280,302,303],{"trials":323,"activeCount":51},[],{"intervention":303,"totalTrials":47,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":334,"NA":340},{"trials":327,"activeCount":51},[],{"trials":329,"activeCount":51},[],{"trials":331,"activeCount":51},[],{"trials":333,"activeCount":51},[],{"trials":335,"activeCount":51},[336],{"nctId":293,"briefTitle":294,"status":105,"phases":337,"primaryCompletion":296,"completion":296,"start":297,"enrollment":298,"conditions":338,"interventions":339},[43],[300],[280,302,303],{"trials":341,"activeCount":51},[],{"intervention":343,"totalTrials":47,"cells":344},"Risperidone Long-Acting Injectable",{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":353,"NA":365},{"trials":346,"activeCount":51},[],{"trials":348,"activeCount":51},[],{"trials":350,"activeCount":51},[],{"trials":352,"activeCount":51},[],{"trials":354,"activeCount":51},[355],{"nctId":356,"briefTitle":357,"status":105,"phases":358,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":364},"NCT00269919","An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia",[43],"2008-08","2005-08",40,[14,363],"Schizoaffective Disorder",[343],{"trials":366,"activeCount":51},[],{"intervention":368,"totalTrials":47,"cells":369},"tramadol hydrochloride \u002Facetaminophen",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":378,"NA":389},{"trials":371,"activeCount":51},[],{"trials":373,"activeCount":51},[],{"trials":375,"activeCount":51},[],{"trials":377,"activeCount":51},[],{"trials":379,"activeCount":51},[380],{"nctId":381,"briefTitle":382,"status":105,"phases":383,"completion":384,"start":360,"enrollment":298,"conditions":385,"interventions":387},"NCT01063842","A Study of the Tolerability of Titrated Dose Tramadol\u002FAcetaminophen Combination Tablet in Korean Patients With Osteoarthritis",[43],"2006-05",[386],"Osteoarthritis",[368,388],"tramadol hydrochloride \u002F acetaminophen and placebo",{"trials":390,"activeCount":51},[],{"intervention":388,"totalTrials":47,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":401,"NA":407},{"trials":394,"activeCount":51},[],{"trials":396,"activeCount":51},[],{"trials":398,"activeCount":51},[],{"trials":400,"activeCount":51},[],{"trials":402,"activeCount":51},[403],{"nctId":381,"briefTitle":382,"status":105,"phases":404,"completion":384,"start":360,"enrollment":298,"conditions":405,"interventions":406},[43],[386],[368,388],{"trials":408,"activeCount":51},[],{"intervention":410,"totalTrials":47,"cells":411},"Meloxicam",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":420,"NA":433},{"trials":413,"activeCount":51},[],{"trials":415,"activeCount":51},[],{"trials":417,"activeCount":51},[],{"trials":419,"activeCount":51},[],{"trials":421,"activeCount":51},[422],{"nctId":423,"briefTitle":424,"status":105,"phases":425,"primaryCompletion":426,"completion":426,"start":427,"enrollment":428,"conditions":429,"interventions":430},"NCT00635349","A Comparative Study of Tramadol Hydrochloride Plus Acetaminophen Tablets Maintenance Versus Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Maintenance in Participants With Knee Osteoarthritis",[43],"2009-04","2007-05",143,[386],[410,431,432],"Aceclofenac","Tramadol Hydrochloride Plus Acetaminophen",{"trials":434,"activeCount":51},[],{"intervention":431,"totalTrials":47,"cells":436},{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":443,"PHASE4":445,"NA":451},{"trials":438,"activeCount":51},[],{"trials":440,"activeCount":51},[],{"trials":442,"activeCount":51},[],{"trials":444,"activeCount":51},[],{"trials":446,"activeCount":51},[447],{"nctId":423,"briefTitle":424,"status":105,"phases":448,"primaryCompletion":426,"completion":426,"start":427,"enrollment":428,"conditions":449,"interventions":450},[43],[386],[410,431,432],{"trials":452,"activeCount":51},[],{"intervention":432,"totalTrials":47,"cells":454},{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":461,"PHASE4":463,"NA":469},{"trials":456,"activeCount":51},[],{"trials":458,"activeCount":51},[],{"trials":460,"activeCount":51},[],{"trials":462,"activeCount":51},[],{"trials":464,"activeCount":51},[465],{"nctId":423,"briefTitle":424,"status":105,"phases":466,"primaryCompletion":426,"completion":426,"start":427,"enrollment":428,"conditions":467,"interventions":468},[43],[386],[410,431,432],{"trials":470,"activeCount":51},[],{"intervention":472,"totalTrials":47,"cells":473},"Rabeprazole",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":482,"NA":493},{"trials":475,"activeCount":51},[],{"trials":477,"activeCount":51},[],{"trials":479,"activeCount":51},[],{"trials":481,"activeCount":51},[],{"trials":483,"activeCount":51},[484],{"nctId":485,"briefTitle":486,"status":105,"phases":487,"primaryCompletion":359,"completion":359,"start":427,"enrollment":488,"conditions":489,"interventions":491},"NCT01008696","An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis",[43],217,[490],"Reflux Esophagitis",[472,492],"Lansoprazole",{"trials":494,"activeCount":51},[],{"intervention":492,"totalTrials":47,"cells":496},{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":501,"PHASE3":503,"PHASE4":505,"NA":511},{"trials":498,"activeCount":51},[],{"trials":500,"activeCount":51},[],{"trials":502,"activeCount":51},[],{"trials":504,"activeCount":51},[],{"trials":506,"activeCount":51},[507],{"nctId":485,"briefTitle":486,"status":105,"phases":508,"primaryCompletion":359,"completion":359,"start":427,"enrollment":488,"conditions":509,"interventions":510},[43],[490],[472,492],{"trials":512,"activeCount":51},[],{"intervention":514,"totalTrials":47,"cells":515},"Oxybutynin chloride OROS",{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":524,"NA":536},{"trials":517,"activeCount":51},[],{"trials":519,"activeCount":51},[],{"trials":521,"activeCount":51},[],{"trials":523,"activeCount":51},[],{"trials":525,"activeCount":51},[526],{"nctId":527,"briefTitle":528,"status":105,"phases":529,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":535},"NCT00613327","An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants",[43],"2008-06","2007-09",345,[534],"Urinary Bladder, Overactive",[514],{"trials":537,"activeCount":51},[],{"intervention":170,"totalTrials":47,"cells":539},{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":546,"PHASE4":548,"NA":554},{"trials":541,"activeCount":51},[],{"trials":543,"activeCount":51},[],{"trials":545,"activeCount":51},[],{"trials":547,"activeCount":51},[],{"trials":549,"activeCount":51},[550],{"nctId":163,"briefTitle":164,"status":105,"phases":551,"primaryCompletion":108,"completion":108,"start":166,"enrollment":167,"conditions":552,"interventions":553},[43],[14],[170,171],{"trials":555,"activeCount":51},[],{"intervention":557,"totalTrials":47,"cells":558},"Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride",{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":565,"PHASE4":567,"NA":579},{"trials":560,"activeCount":51},[],{"trials":562,"activeCount":51},[],{"trials":564,"activeCount":51},[],{"trials":566,"activeCount":51},[],{"trials":568,"activeCount":51},[569],{"nctId":570,"briefTitle":571,"status":105,"phases":572,"primaryCompletion":573,"completion":573,"start":574,"enrollment":575,"conditions":576,"interventions":578},"NCT01012622","An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)",[43],"2009-08","2008-09",142,[577],"Attention Deficit Disorder With Hyperactivity",[557],{"trials":580,"activeCount":51},[],{"intervention":582,"totalTrials":47,"cells":583},"topamax",{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":590,"PHASE4":592,"NA":604},{"trials":585,"activeCount":51},[],{"trials":587,"activeCount":51},[],{"trials":589,"activeCount":51},[],{"trials":591,"activeCount":51},[],{"trials":593,"activeCount":51},[594],{"nctId":595,"briefTitle":596,"status":105,"phases":597,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":603},"NCT00216567","Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy",[43],"2006-02","2002-12",114,[602],"Epilepsy, Rolandic",[582],{"trials":605,"activeCount":51},[],{"intervention":607,"totalTrials":47,"cells":608},"galantamine hydrobromide",{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":615,"PHASE4":617,"NA":629},{"trials":610,"activeCount":51},[],{"trials":612,"activeCount":51},[],{"trials":614,"activeCount":51},[],{"trials":616,"activeCount":51},[],{"trials":618,"activeCount":51},[619],{"nctId":620,"briefTitle":621,"status":105,"phases":622,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":628},"NCT00216515","The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type",[43],"2005-11","2004-03",102,[627],"Alzheimer Disease",[607],{"trials":630,"activeCount":51},[],{"intervention":632,"totalTrials":47,"cells":633},"tramadol hydrochloride + acetaminophen",{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":640,"PHASE4":642,"NA":653},{"trials":635,"activeCount":51},[],{"trials":637,"activeCount":51},[],{"trials":639,"activeCount":51},[],{"trials":641,"activeCount":51},[],{"trials":643,"activeCount":51},[644],{"nctId":645,"briefTitle":646,"status":105,"phases":647,"completion":648,"enrollment":649,"conditions":650,"interventions":652},"NCT00246168","ULTRACET (Tramadol Hydrochloride and Acetaminophen) for the Treatment of Rheumatoid Arthritis Pain.",[43],"2005-06",277,[651],"Arthritis, Rheumatoid",[632],{"trials":654,"activeCount":51},[],{"intervention":656,"totalTrials":47,"cells":657},"Paliperdidone ER",{"EARLY_PHASE1":658,"PHASE1":660,"PHASE2":662,"PHASE3":664,"PHASE4":666,"NA":679},{"trials":659,"activeCount":51},[],{"trials":661,"activeCount":51},[],{"trials":663,"activeCount":51},[],{"trials":665,"activeCount":51},[],{"trials":667,"activeCount":51},[668],{"nctId":669,"briefTitle":670,"status":671,"phases":672,"primaryCompletion":673,"completion":673,"start":674,"enrollment":675,"conditions":676,"interventions":677},"NCT01592201","A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug","TERMINATED",[43],"2013-06","2012-07",13,[14],[656,678],"Aripiprazole, olanzapine and risperidone",{"trials":680,"activeCount":51},[],{"intervention":678,"totalTrials":47,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":691,"NA":697},{"trials":684,"activeCount":51},[],{"trials":686,"activeCount":51},[],{"trials":688,"activeCount":51},[],{"trials":690,"activeCount":51},[],{"trials":692,"activeCount":51},[693],{"nctId":669,"briefTitle":670,"status":671,"phases":694,"primaryCompletion":673,"completion":673,"start":674,"enrollment":675,"conditions":695,"interventions":696},[43],[14],[656,678],{"trials":698,"activeCount":51},[],{"intervention":700,"totalTrials":47,"cells":701},"Hydromorphone HCl OROS",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":720},{"trials":703,"activeCount":51},[],{"trials":705,"activeCount":51},[],{"trials":707,"activeCount":51},[],{"trials":709,"activeCount":51},[],{"trials":711,"activeCount":51},[712],{"nctId":713,"briefTitle":714,"status":105,"phases":715,"primaryCompletion":573,"completion":573,"start":226,"enrollment":716,"conditions":717,"interventions":719},"NCT01006356","An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer",[43],141,[718,17],"Cancer",[700],{"trials":721,"activeCount":51},[],{"intervention":723,"totalTrials":47,"cells":724},"OROS Methylphenidate HCl",{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":733,"NA":743},{"trials":726,"activeCount":51},[],{"trials":728,"activeCount":51},[],{"trials":730,"activeCount":51},[],{"trials":732,"activeCount":51},[],{"trials":734,"activeCount":51},[735],{"nctId":736,"briefTitle":737,"status":105,"phases":738,"primaryCompletion":739,"completion":739,"start":296,"enrollment":740,"conditions":741,"interventions":742},"NCT01060150","An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[43],"2010-04",115,[577],[723],{"trials":744,"activeCount":51},[],{"intervention":746,"totalTrials":47,"cells":747},"Tramadol hydrochloride\u002F Acetaminophen",{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":768},{"trials":749,"activeCount":51},[],{"trials":751,"activeCount":51},[],{"trials":753,"activeCount":51},[],{"trials":755,"activeCount":51},[],{"trials":757,"activeCount":51},[758],{"nctId":759,"briefTitle":760,"status":105,"phases":761,"primaryCompletion":226,"completion":226,"start":762,"enrollment":763,"conditions":764,"interventions":766},"NCT00634543","A Study to Compare Safety and Efficacy of Tramadol Hydrochloride\u002FAcetaminophen With Gabapentin in Participants With Diabetic Neuropathy",[43],"2006-12",162,[765],"Diabetic Neuropathy",[746,767],"Gabapentin",{"trials":769,"activeCount":51},[],{"intervention":767,"totalTrials":47,"cells":771},{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":778,"PHASE4":780,"NA":786},{"trials":773,"activeCount":51},[],{"trials":775,"activeCount":51},[],{"trials":777,"activeCount":51},[],{"trials":779,"activeCount":51},[],{"trials":781,"activeCount":51},[782],{"nctId":759,"briefTitle":760,"status":105,"phases":783,"primaryCompletion":226,"completion":226,"start":762,"enrollment":763,"conditions":784,"interventions":785},[43],[765],[746,767],{"trials":787,"activeCount":51},[],{"intervention":789,"totalTrials":47,"cells":790},"Tramadol HCl\u002FAcetaminophen ER",{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":795,"PHASE3":797,"PHASE4":810,"NA":812},{"trials":792,"activeCount":51},[],{"trials":794,"activeCount":51},[],{"trials":796,"activeCount":51},[],{"trials":798,"activeCount":51},[799],{"nctId":800,"briefTitle":801,"status":105,"phases":802,"primaryCompletion":134,"completion":803,"start":804,"enrollment":805,"conditions":806,"interventions":808},"NCT01814878","A Study Comparing the Effectiveness and Safety of Extended Release (ER) Tramadol Hydrochloride (HCl)\u002FAcetaminophen With Immediate Release (IR) Tramadol HCl\u002FAcetaminophen in Participants With Moderate to Severe Postoperative Pain",[42],"2011-02","2009-11",320,[807],"Pain, Postoperative",[789,809],"Tramadol HCl\u002FAcetaminophen IR",{"trials":811,"activeCount":51},[],{"trials":813,"activeCount":51},[],{"intervention":809,"totalTrials":47,"cells":815},{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":820,"PHASE3":822,"PHASE4":828,"NA":830},{"trials":817,"activeCount":51},[],{"trials":819,"activeCount":51},[],{"trials":821,"activeCount":51},[],{"trials":823,"activeCount":51},[824],{"nctId":800,"briefTitle":801,"status":105,"phases":825,"primaryCompletion":134,"completion":803,"start":804,"enrollment":805,"conditions":826,"interventions":827},[42],[807],[789,809],{"trials":829,"activeCount":51},[],{"trials":831,"activeCount":51},[],{"intervention":833,"totalTrials":47,"cells":834},"Tramadol HCl\u002Facetaminophen Extended Release",{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":841,"PHASE4":853,"NA":855},{"trials":836,"activeCount":51},[],{"trials":838,"activeCount":51},[],{"trials":840,"activeCount":51},[],{"trials":842,"activeCount":51},[843],{"nctId":844,"briefTitle":845,"status":105,"phases":846,"primaryCompletion":847,"completion":847,"start":848,"enrollment":849,"conditions":850,"interventions":852},"NCT01112267","An Efficacy and Safety Study of Extended Release (ER) Tramadol Hydrochloride (HCl)\u002FAcetaminophen in Participants With Chronic Low-Back Pain",[42],"2009-10","2009-05",248,[851],"Low Back Pain",[833,833],{"trials":854,"activeCount":51},[],{"trials":856,"activeCount":51},[],{"intervention":858,"totalTrials":8,"cells":859},"Acetaminophen",{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":883,"PHASE3":885,"PHASE4":887,"NA":889},{"trials":861,"activeCount":51},[],{"trials":863,"activeCount":51},[864,874],{"nctId":865,"briefTitle":866,"status":105,"phases":867,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":873},"NCT04214691","A Study of Newly Formulated Tylenol Tablet (Acetaminophen) and Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetaminophen) in Healthy Participants",[40],"2020-01-16","2020-02-07","2019-12-17",30,[22],[858],{"nctId":875,"briefTitle":876,"status":105,"phases":877,"primaryCompletion":878,"completion":879,"start":880,"enrollment":871,"conditions":881,"interventions":882},"NCT04230252","A Study of the Newly Formulated Tylenol Tablet (Acetaminophen) to the Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetaminophen) in Healthy Participants",[40],"2020-02-10","2020-03-23","2020-01-07",[22],[858],{"trials":884,"activeCount":51},[],{"trials":886,"activeCount":51},[],{"trials":888,"activeCount":51},[],{"trials":890,"activeCount":51},[],{"intervention":892,"totalTrials":47,"cells":893},"Tramadol HCl 75 mg\u002FAcetaminophen 650 mg",{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":907,"PHASE3":909,"PHASE4":911,"NA":913},{"trials":895,"activeCount":51},[],{"trials":897,"activeCount":51},[898],{"nctId":899,"briefTitle":900,"status":105,"phases":901,"primaryCompletion":902,"completion":902,"start":903,"enrollment":904,"conditions":905,"interventions":906},"NCT01778075","A Study to Assess the Bioequivalence of a New ULTRACET Extended Release (ER) Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition",[40],"2013-02","2012-12",56,[22],[892,892],{"trials":908,"activeCount":51},[],{"trials":910,"activeCount":51},[],{"trials":912,"activeCount":51},[],{"trials":914,"activeCount":51},[],{"intervention":916,"totalTrials":47,"cells":917},"Risperdal OD Tab. 2mg",{"EARLY_PHASE1":918,"PHASE1":920,"PHASE2":930,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":919,"activeCount":51},[],{"trials":921,"activeCount":51},[922],{"nctId":923,"briefTitle":924,"status":105,"phases":925,"primaryCompletion":573,"completion":573,"start":573,"enrollment":926,"conditions":927,"interventions":928},"NCT02012049","Bioequivalence Test for Risperdal 2mg of Janssen Korea",[40],36,[22],[916,929],"Risperdal Quicklet Tab. 2mg",{"trials":931,"activeCount":51},[],{"trials":933,"activeCount":51},[],{"trials":935,"activeCount":51},[],{"trials":937,"activeCount":51},[],{"intervention":929,"totalTrials":47,"cells":939},{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":948,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":941,"activeCount":51},[],{"trials":943,"activeCount":51},[944],{"nctId":923,"briefTitle":924,"status":105,"phases":945,"primaryCompletion":573,"completion":573,"start":573,"enrollment":926,"conditions":946,"interventions":947},[40],[22],[916,929],{"trials":949,"activeCount":51},[],{"trials":951,"activeCount":51},[],{"trials":953,"activeCount":51},[],{"trials":955,"activeCount":51},[],{"intervention":957,"totalTrials":958,"cells":959},"No intervention",8,{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":966,"PHASE4":968,"NA":970},{"trials":961,"activeCount":51},[],{"trials":963,"activeCount":51},[],{"trials":965,"activeCount":51},[],{"trials":967,"activeCount":51},[],{"trials":969,"activeCount":51},[],{"trials":971,"activeCount":51},[972,980,990,998,1006,1016,1025,1033],{"nctId":973,"briefTitle":974,"status":105,"phases":975,"primaryCompletion":976,"completion":976,"start":804,"enrollment":977,"conditions":978,"interventions":979},"NCT01060202","Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib",[],"2011-07",60,[20],[957],{"nctId":981,"briefTitle":982,"status":671,"phases":983,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":987,"interventions":989},"NCT01802359","A Study to Evaluate the Safety and Effectiveness of Mirodenafil in Korean Patients With Erectile Dysfunction",[],"2012-05-31","2011-11-07",379,[988],"Erectile Dysfunction",[957],{"nctId":991,"briefTitle":992,"status":105,"phases":993,"primaryCompletion":125,"completion":125,"start":994,"enrollment":249,"conditions":995,"interventions":997},"NCT01041846","A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome",[],"2008-12",[996],"Myelodysplastic Syndrome",[957],{"nctId":999,"briefTitle":1000,"status":105,"phases":1001,"primaryCompletion":674,"completion":674,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1005},"NCT01819805","A Study to Assess the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol Hydrochloride and Acetaminophen",[],"2011-09",1065,[27],[957],{"nctId":1007,"briefTitle":1008,"status":105,"phases":1009,"primaryCompletion":1010,"completion":1010,"start":1011,"enrollment":1012,"conditions":1013,"interventions":1015},"NCT01741844","A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence",[],"2014-07","2012-09",57,[1014],"Acquired Immune Deficiency Syndrome",[957],{"nctId":1017,"briefTitle":1018,"status":105,"phases":1019,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1022,"conditions":1023,"interventions":1024},"NCT01819818","A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients",[],"2019-11-29","2011-05-23",3267,[14],[957],{"nctId":1026,"briefTitle":1027,"status":105,"phases":1028,"primaryCompletion":1029,"completion":1029,"start":674,"enrollment":1030,"conditions":1031,"interventions":1032},"NCT01741831","A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista",[],"2016-10",225,[1014],[957],{"nctId":1034,"briefTitle":1035,"status":105,"phases":1036,"primaryCompletion":1037,"completion":1037,"start":994,"enrollment":1038,"conditions":1039,"interventions":1040},"NCT01816503","Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study",[],"2009-07",636,[17],[957],{"intervention":1042,"totalTrials":1043,"cells":1044},"bortezomib",5,{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1049,"PHASE3":1051,"PHASE4":1053,"NA":1055},{"trials":1046,"activeCount":51},[],{"trials":1048,"activeCount":51},[],{"trials":1050,"activeCount":51},[],{"trials":1052,"activeCount":51},[],{"trials":1054,"activeCount":51},[],{"trials":1056,"activeCount":51},[1057,1066,1073,1085,1093],{"nctId":1058,"briefTitle":1059,"status":105,"phases":1060,"primaryCompletion":1061,"completion":1061,"start":1062,"enrollment":1063,"conditions":1064,"interventions":1065},"NCT01005628","Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)",[],"2012-03","2006-06",1121,[20],[1042],{"nctId":1067,"briefTitle":1068,"status":105,"phases":1069,"primaryCompletion":117,"completion":117,"start":1070,"enrollment":904,"conditions":1071,"interventions":1072},"NCT01030302","A Retreatment Study With Bortezomib for Multiple Myeloma",[],"2008-11",[20],[1042],{"nctId":1074,"briefTitle":1075,"status":105,"phases":1076,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":1079,"conditions":1080,"interventions":1081},"NCT02474563","Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma",[],"2014-05","2011-05",171,[20],[1082,1083,1084],"Bortezomib","Melphalan","Prednisone",{"nctId":1086,"briefTitle":1087,"status":105,"phases":1088,"primaryCompletion":296,"completion":296,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1092},"NCT01021592","Quality of Life in Multiple Myeloma Patients Treated With Bortezomib",[],"2007-03",140,[20],[1042],{"nctId":1094,"briefTitle":1095,"status":105,"phases":1096,"primaryCompletion":804,"completion":804,"start":1097,"enrollment":1098,"conditions":1099,"interventions":1100},"NCT01026701","Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.",[],"2008-03",104,[20],[1042],{"intervention":1102,"totalTrials":9,"cells":1103},"fentanyl matrix",{"EARLY_PHASE1":1104,"PHASE1":1106,"PHASE2":1108,"PHASE3":1110,"PHASE4":1112,"NA":1122},{"trials":1105,"activeCount":51},[],{"trials":1107,"activeCount":51},[],{"trials":1109,"activeCount":51},[],{"trials":1111,"activeCount":51},[],{"trials":1113,"activeCount":51},[1114],{"nctId":1115,"briefTitle":1116,"status":105,"phases":1117,"primaryCompletion":427,"completion":427,"start":384,"enrollment":1118,"conditions":1119,"interventions":1121},"NCT01060137","Fentanyl Matrix in Lung Cancer Pain",[43],268,[1120,17],"Lung Cancer",[1102],{"trials":1123,"activeCount":51},[1124,1134],{"nctId":1125,"briefTitle":1126,"status":105,"phases":1127,"primaryCompletion":1128,"completion":1128,"start":359,"enrollment":1129,"conditions":1130,"interventions":1133},"NCT01119885","Observational Study Investigating the Effectiveness of Fentanyl Matrix in Relieving Pain and Improving Function in Patients With Osteoarthritis of the Knee or Hip",[],"2009-01",742,[17,1131,1132],"Osteoarthritis, Hip","Osteoarthritis, Knee",[1102,1102],{"nctId":1135,"briefTitle":1136,"status":105,"phases":1137,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":1141,"interventions":1142},"NCT01688583","The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement",[],"2013-03","2011-12",410,[27],[1143],"Fentanyl matrix",{"intervention":1145,"totalTrials":9,"cells":1146},"Itraconazole",{"EARLY_PHASE1":1147,"PHASE1":1149,"PHASE2":1151,"PHASE3":1153,"PHASE4":1155,"NA":1167},{"trials":1148,"activeCount":51},[],{"trials":1150,"activeCount":51},[],{"trials":1152,"activeCount":51},[],{"trials":1154,"activeCount":51},[],{"trials":1156,"activeCount":51},[1157],{"nctId":1158,"briefTitle":1159,"status":105,"phases":1160,"primaryCompletion":848,"completion":1161,"start":1162,"enrollment":1163,"conditions":1164,"interventions":1166},"NCT00871728","Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules",[43],"2009-12","2007-01",132,[1165],"Onychomycosis, Toe",[1145],{"trials":1168,"activeCount":51},[1169,1176],{"nctId":1170,"briefTitle":1171,"status":105,"phases":1172,"primaryCompletion":1002,"completion":1002,"start":1078,"enrollment":1173,"conditions":1174,"interventions":1175},"NCT01706562","A Study of Empirical Antifungal Therapy With Itraconazole",[],138,[29],[1145],{"nctId":1177,"briefTitle":1178,"status":105,"phases":1179,"primaryCompletion":125,"completion":125,"start":1037,"enrollment":1180,"conditions":1181,"interventions":1184},"NCT01021683","The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants",[],203,[1182,29,1183],"Hematologic Neoplasms","Fever",[1145],{"intervention":1186,"totalTrials":8,"cells":1187},"Infliximab",{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1194,"PHASE4":1206,"NA":1208},{"trials":1189,"activeCount":51},[],{"trials":1191,"activeCount":51},[],{"trials":1193,"activeCount":51},[],{"trials":1195,"activeCount":51},[1196],{"nctId":1197,"briefTitle":1198,"status":105,"phases":1199,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1205},"NCT02505568","A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease",[42],"2018-07-13","2015-07-22",33,[1204],"Behcet Disease",[1186],{"trials":1207,"activeCount":51},[],{"trials":1209,"activeCount":51},[1210],{"nctId":1211,"briefTitle":1212,"status":105,"phases":1213,"primaryCompletion":1214,"completion":1214,"start":1215,"enrollment":1216,"conditions":1217,"interventions":1220},"NCT00724529","Post Marketing Surveillance of Remicade",[],"2011-08","2007-06",938,[1218,1219],"Crohn's Disease","Ankylosing Spondylitis",[1186],{"intervention":1222,"totalTrials":8,"cells":1223},"Topiramate",{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1230,"PHASE4":1232,"NA":1234},{"trials":1225,"activeCount":51},[],{"trials":1227,"activeCount":51},[],{"trials":1229,"activeCount":51},[],{"trials":1231,"activeCount":51},[],{"trials":1233,"activeCount":51},[],{"trials":1235,"activeCount":51},[1236,1244],{"nctId":1237,"briefTitle":1238,"status":105,"phases":1239,"primaryCompletion":848,"completion":848,"start":1240,"enrollment":1241,"conditions":1242,"interventions":1243},"NCT01682681","An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy",[],"2007-07",1234,[25],[1222],{"nctId":1245,"briefTitle":1246,"status":105,"phases":1247,"primaryCompletion":426,"completion":426,"start":1248,"enrollment":1090,"conditions":1249,"interventions":1254},"NCT01030094","A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy",[],"2007-02",[1250,1251,25,1252,1253],"Seizures","Convulsions","Osteopenia","Osteoporosis",[1222,1255,1256,1257],"Carbamazepine","Valproic acid","Normal control",{"intervention":1259,"totalTrials":8,"cells":1260},"Rabeprazole Sodium",{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1267,"PHASE4":1269,"NA":1271},{"trials":1262,"activeCount":51},[],{"trials":1264,"activeCount":51},[],{"trials":1266,"activeCount":51},[],{"trials":1268,"activeCount":51},[],{"trials":1270,"activeCount":51},[],{"trials":1272,"activeCount":51},[1273,1281],{"nctId":1274,"briefTitle":1275,"status":105,"phases":1276,"primaryCompletion":248,"completion":248,"start":530,"enrollment":1277,"conditions":1278,"interventions":1280},"NCT01018160","Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea",[],1197,[1279],"Gastroesophageal Reflux",[1259],{"nctId":1282,"briefTitle":1283,"status":105,"phases":1284,"primaryCompletion":109,"completion":109,"start":531,"enrollment":1285,"conditions":1286,"interventions":1288},"NCT00614536","Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period",[],1142,[1279,1287],"Pharyngeal Diseases",[1259],{"intervention":1290,"totalTrials":8,"cells":1291},"OROS Hydromorphone",{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1298,"PHASE4":1300,"NA":1310},{"trials":1293,"activeCount":51},[],{"trials":1295,"activeCount":51},[],{"trials":1297,"activeCount":51},[],{"trials":1299,"activeCount":51},[],{"trials":1301,"activeCount":51},[1302],{"nctId":1303,"briefTitle":1304,"status":105,"phases":1305,"primaryCompletion":1011,"completion":1011,"start":1139,"enrollment":1306,"conditions":1307,"interventions":1308},"NCT01621100","Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients",[43],106,[31],[1309],"OROS hydromorphone",{"trials":1311,"activeCount":51},[1312],{"nctId":1313,"briefTitle":1314,"status":105,"phases":1315,"primaryCompletion":1161,"completion":1161,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1319},"NCT01273454","An Observational Study to Investigate Clinical Usefulness of OROS Hydromorphone in Korean Cancer Patients",[],"2009-06",648,[17],[1290],{"intervention":1321,"totalTrials":8,"cells":1322},"Galantamine",{"EARLY_PHASE1":1323,"PHASE1":1325,"PHASE2":1327,"PHASE3":1329,"PHASE4":1331,"NA":1342},{"trials":1324,"activeCount":51},[],{"trials":1326,"activeCount":51},[],{"trials":1328,"activeCount":51},[],{"trials":1330,"activeCount":51},[],{"trials":1332,"activeCount":51},[1333],{"nctId":1334,"briefTitle":1335,"status":105,"phases":1336,"primaryCompletion":248,"completion":248,"start":1337,"enrollment":1338,"conditions":1339,"interventions":1341},"NCT01054976","The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease",[43],"2006-10",99,[1340],"Alzheimer's Disease",[1321],{"trials":1343,"activeCount":51},[1344],{"nctId":1345,"briefTitle":1346,"status":105,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1089,"enrollment":1349,"conditions":1350,"interventions":1351},"NCT01734395","A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease",[],"2008-01",1882,[1340],[1321],{"intervention":1353,"totalTrials":47,"cells":1354},"Ustekinumab",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1361,"PHASE4":1363,"NA":1365},{"trials":1356,"activeCount":51},[],{"trials":1358,"activeCount":51},[],{"trials":1360,"activeCount":51},[],{"trials":1362,"activeCount":51},[],{"trials":1364,"activeCount":51},[],{"trials":1366,"activeCount":51},[1367],{"nctId":1368,"briefTitle":1369,"status":105,"phases":1370,"primaryCompletion":1371,"completion":1371,"start":1372,"enrollment":1373,"conditions":1374,"interventions":1376},"NCT03942120","Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)",[],"2022-01-14","2019-04-08",685,[1375],"Crohn Disease",[1353],{"intervention":1378,"totalTrials":47,"cells":1379},"Tramadol\u002Facetaminophen",{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1388,"NA":1390},{"trials":1381,"activeCount":51},[],{"trials":1383,"activeCount":51},[],{"trials":1385,"activeCount":51},[],{"trials":1387,"activeCount":51},[],{"trials":1389,"activeCount":51},[],{"trials":1391,"activeCount":51},[1392],{"nctId":1393,"briefTitle":1394,"status":105,"phases":1395,"primaryCompletion":1396,"completion":1396,"start":531,"enrollment":1397,"conditions":1398,"interventions":1400},"NCT00642837","A Study on Health - Related Quality of Life in Patients With Rheumatic Diseases Taking Tramadol 37.5mg\u002FAcetaminophen 325mg Tablets",[],"2008-05",982,[1399],"Rheumatic Diseases",[1378,1378,1378,1378,1378,1378,1378,1378,1378,1378],{"intervention":1402,"totalTrials":47,"cells":1403},"fentanyl",{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1405,"activeCount":51},[],{"trials":1407,"activeCount":51},[],{"trials":1409,"activeCount":51},[],{"trials":1411,"activeCount":51},[],{"trials":1413,"activeCount":51},[],{"trials":1415,"activeCount":51},[1416],{"nctId":1417,"briefTitle":1418,"status":105,"phases":1419,"primaryCompletion":994,"completion":994,"start":1396,"enrollment":1420,"conditions":1421,"interventions":1422},"NCT00797017","Study on Impact of Fentanyl Matrix on Improvement of Pain and Functioning in Spinal Disorder-related Pain",[],1576,[851],[1402,1402,1402,1402,1402,1402,1402],{"intervention":1424,"totalTrials":47,"cells":1425},"Pts. w\u002F neutropenic fever associated w\u002F hematologic malignancy",{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1427,"activeCount":51},[],{"trials":1429,"activeCount":51},[],{"trials":1431,"activeCount":51},[],{"trials":1433,"activeCount":51},[],{"trials":1435,"activeCount":51},[],{"trials":1437,"activeCount":51},[1438],{"nctId":1439,"briefTitle":1440,"status":105,"phases":1441,"primaryCompletion":248,"completion":248,"start":359,"enrollment":1442,"conditions":1443,"interventions":1445},"NCT01060462","Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients",[],438,[1444,29,1183],"Hematological Malignancies",[1424],{"intervention":1447,"totalTrials":47,"cells":1448},"Methylphenidate hydrochloride",{"EARLY_PHASE1":1449,"PHASE1":1451,"PHASE2":1453,"PHASE3":1455,"PHASE4":1457,"NA":1459},{"trials":1450,"activeCount":51},[],{"trials":1452,"activeCount":51},[],{"trials":1454,"activeCount":51},[],{"trials":1456,"activeCount":51},[],{"trials":1458,"activeCount":51},[],{"trials":1460,"activeCount":51},[1461],{"nctId":1462,"briefTitle":1463,"status":105,"phases":1464,"primaryCompletion":1465,"completion":1465,"start":1466,"enrollment":135,"conditions":1467,"interventions":1469},"NCT01624649","A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors",[],"2014-04","2012-02",[1468],"Attention-deficit Hyperactivity Disorder",[1447,1470],"Atomoxetine",{"intervention":1470,"totalTrials":47,"cells":1472},{"EARLY_PHASE1":1473,"PHASE1":1475,"PHASE2":1477,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1474,"activeCount":51},[],{"trials":1476,"activeCount":51},[],{"trials":1478,"activeCount":51},[],{"trials":1480,"activeCount":51},[],{"trials":1482,"activeCount":51},[],{"trials":1484,"activeCount":51},[1485],{"nctId":1462,"briefTitle":1463,"status":105,"phases":1486,"primaryCompletion":1465,"completion":1465,"start":1466,"enrollment":135,"conditions":1487,"interventions":1488},[],[1468],[1447,1470],{"intervention":1490,"totalTrials":47,"cells":1491},"Hydromorphone HCI OROS",{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1493,"activeCount":51},[],{"trials":1495,"activeCount":51},[],{"trials":1497,"activeCount":51},[],{"trials":1499,"activeCount":51},[],{"trials":1501,"activeCount":51},[],{"trials":1503,"activeCount":51},[1504],{"nctId":1505,"briefTitle":1506,"status":105,"phases":1507,"primaryCompletion":1011,"completion":1508,"start":1002,"enrollment":1509,"conditions":1510,"interventions":1511},"NCT01532895","Clinical Usefulness and Quality of Life of OROS Hydromorphone in Patients Who Have Not Been Treated With a Strong Opioid",[],"2012-10",400,[17],[1490],{"intervention":1513,"totalTrials":47,"cells":1514},"Infliximab; observational study",{"EARLY_PHASE1":1515,"PHASE1":1517,"PHASE2":1519,"PHASE3":1521,"PHASE4":1523,"NA":1525},{"trials":1516,"activeCount":51},[],{"trials":1518,"activeCount":51},[],{"trials":1520,"activeCount":51},[],{"trials":1522,"activeCount":51},[],{"trials":1524,"activeCount":51},[],{"trials":1526,"activeCount":51},[1527],{"nctId":1528,"briefTitle":1529,"status":105,"phases":1530,"primaryCompletion":1531,"completion":1531,"start":427,"enrollment":1532,"conditions":1533,"interventions":1537},"NCT00760669","An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants",[],"2011-04",1061,[1534,651,1535,1536],"Spondylitis, Ankylosing","Psoriasis","Arthritis, Psoriatic",[1513,1538],"Methotrexate; observational study",{"intervention":1538,"totalTrials":47,"cells":1540},{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1547,"PHASE4":1549,"NA":1551},{"trials":1542,"activeCount":51},[],{"trials":1544,"activeCount":51},[],{"trials":1546,"activeCount":51},[],{"trials":1548,"activeCount":51},[],{"trials":1550,"activeCount":51},[],{"trials":1552,"activeCount":51},[1553],{"nctId":1528,"briefTitle":1529,"status":105,"phases":1554,"primaryCompletion":1531,"completion":1531,"start":427,"enrollment":1532,"conditions":1555,"interventions":1556},[],[1534,651,1535,1536],[1513,1538],{"intervention":1558,"totalTrials":47,"cells":1559},"Risperdal Consta",{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1566,"PHASE4":1568,"NA":1570},{"trials":1561,"activeCount":51},[],{"trials":1563,"activeCount":51},[],{"trials":1565,"activeCount":51},[],{"trials":1567,"activeCount":51},[],{"trials":1569,"activeCount":51},[],{"trials":1571,"activeCount":51},[1572],{"nctId":1573,"briefTitle":1574,"status":105,"phases":1575,"primaryCompletion":1316,"completion":1316,"start":1576,"enrollment":1577,"conditions":1578,"interventions":1585},"NCT00294008","A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)",[],"2004-12",230,[14,1579,1580,1581,1582,1583,1584],"Tranquilizing Agents","Mental Disorders","Therapeutic Uses","Physiological Effects of Drugs","Psychotropic Drugs","Antipsychotic Agents",[1558],{"intervention":1587,"totalTrials":47,"cells":1588},"Prucalopride; observational study",{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1595,"PHASE4":1597,"NA":1599},{"trials":1590,"activeCount":51},[],{"trials":1592,"activeCount":51},[],{"trials":1594,"activeCount":51},[],{"trials":1596,"activeCount":51},[],{"trials":1598,"activeCount":51},[],{"trials":1600,"activeCount":51},[1601],{"nctId":1602,"briefTitle":1603,"status":105,"phases":1604,"primaryCompletion":1605,"completion":1605,"start":1606,"enrollment":1607,"conditions":1608,"interventions":1610},"NCT01902537","An Observational Study to Evaluate the Quality of Life in Korean Female Participants With Chronic Constipation",[],"2013-04","2012-08",150,[1609],"Constipation",[1587],{"intervention":1083,"totalTrials":47,"cells":1612},{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1619,"PHASE4":1621,"NA":1623},{"trials":1614,"activeCount":51},[],{"trials":1616,"activeCount":51},[],{"trials":1618,"activeCount":51},[],{"trials":1620,"activeCount":51},[],{"trials":1622,"activeCount":51},[],{"trials":1624,"activeCount":51},[1625],{"nctId":1074,"briefTitle":1075,"status":105,"phases":1626,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":1079,"conditions":1627,"interventions":1628},[],[20],[1082,1083,1084],{"intervention":1084,"totalTrials":47,"cells":1630},{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1635,"PHASE3":1637,"PHASE4":1639,"NA":1641},{"trials":1632,"activeCount":51},[],{"trials":1634,"activeCount":51},[],{"trials":1636,"activeCount":51},[],{"trials":1638,"activeCount":51},[],{"trials":1640,"activeCount":51},[],{"trials":1642,"activeCount":51},[1643],{"nctId":1074,"briefTitle":1075,"status":105,"phases":1644,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":1079,"conditions":1645,"interventions":1646},[],[20],[1082,1083,1084],{"intervention":1648,"totalTrials":47,"cells":1649},"decitabine",{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1656,"PHASE4":1658,"NA":1660},{"trials":1651,"activeCount":51},[],{"trials":1653,"activeCount":51},[],{"trials":1655,"activeCount":51},[],{"trials":1657,"activeCount":51},[],{"trials":1659,"activeCount":51},[],{"trials":1661,"activeCount":51},[1662],{"nctId":1663,"briefTitle":1664,"status":105,"phases":1665,"primaryCompletion":1666,"completion":1666,"start":108,"enrollment":1667,"conditions":1668,"interventions":1670},"NCT01400633","An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome",[],"2014-03",156,[1669],"Myelodysplastic Syndromes",[1648],{"intervention":1255,"totalTrials":47,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1681,"NA":1683},{"trials":1674,"activeCount":51},[],{"trials":1676,"activeCount":51},[],{"trials":1678,"activeCount":51},[],{"trials":1680,"activeCount":51},[],{"trials":1682,"activeCount":51},[],{"trials":1684,"activeCount":51},[1685],{"nctId":1245,"briefTitle":1246,"status":105,"phases":1686,"primaryCompletion":426,"completion":426,"start":1248,"enrollment":1090,"conditions":1687,"interventions":1688},[],[1250,1251,25,1252,1253],[1222,1255,1256,1257],{"intervention":1256,"totalTrials":47,"cells":1690},{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1695,"PHASE3":1697,"PHASE4":1699,"NA":1701},{"trials":1692,"activeCount":51},[],{"trials":1694,"activeCount":51},[],{"trials":1696,"activeCount":51},[],{"trials":1698,"activeCount":51},[],{"trials":1700,"activeCount":51},[],{"trials":1702,"activeCount":51},[1703],{"nctId":1245,"briefTitle":1246,"status":105,"phases":1704,"primaryCompletion":426,"completion":426,"start":1248,"enrollment":1090,"conditions":1705,"interventions":1706},[],[1250,1251,25,1252,1253],[1222,1255,1256,1257],{"intervention":1257,"totalTrials":47,"cells":1708},{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1713,"PHASE3":1715,"PHASE4":1717,"NA":1719},{"trials":1710,"activeCount":51},[],{"trials":1712,"activeCount":51},[],{"trials":1714,"activeCount":51},[],{"trials":1716,"activeCount":51},[],{"trials":1718,"activeCount":51},[],{"trials":1720,"activeCount":51},[1721],{"nctId":1245,"briefTitle":1246,"status":105,"phases":1722,"primaryCompletion":426,"completion":426,"start":1248,"enrollment":1090,"conditions":1723,"interventions":1724},[],[1250,1251,25,1252,1253],[1222,1255,1256,1257]]